This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC
Voluntarily participate in clinical research and sign written informed consent
Male or female patients aged 18-75 years old (including the critical value)
Histologically or cytologically confirmed SCLC
Clinically diagnosed as IIB-IIIB ( N2) stage (AJCC 8th edition cancer staging)
Mixed SCLC confirmed by histology or cytology
Previously received systemic anti-tumor treatment for small cell lung cancer, including but not limited to chemotherapy, immunotherapy, and radiotherapy
Other active malignant tumors within 5 years or at the same time. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, and carcinoma in situ of the breast, can be enrolled
Those who are planning to undergo or have received organs in the past or bone marrow transplant patients
Guangdong Provincial People's Hospital
Lead sponsor
Liaoning Cancer Hospital & Institute
Collaborator
Guangzhou No.12 People's Hospital
Collaborator
Second Xiangya Hospital of Central South University
Collaborator